News

16th Invitation to manufacturers and suppliers of medicinal products for HIV infections and related diseases to submit and Expression of Interest (EOI) for product evaluation to the WHO Prequalification Team: medicines

The following products were deleted:

  • Efavirenz, tablet 200mg scored and preferably dispersible
  • Nevirapine, tablet 50mg scored and dispersible
  • Raltegravir, dispersible tablet 5mg (scored) and 50mg (scored)
  • Zidovudine, tablet 60mg scored and dispersible
  • Abacavir/Lamivudine, dispersible tablet (scored), 60mg/30mg
  • Abacavir/Lamivudine/Efavirenz, tablet 150/75/150 mg scored
  • Lamivudine/Zidovudine, granules/minitablets/pellets 15 mg /30 mg co-mixed with Lopinavir/Ritonavir, granules/minitablets/pellets (heat stable) 40mg/10mg
  • Lamivudine/Zidovudine, granules/minitablets/pellets 15 mg /30 mg co-mixed with Lopinavir/Ritonavir, granules/minitablets/pellets (heat stable) 40mg/10mg
  • Lopinavir/Ritonavir, oral solution 80/20 mg/ml
  • Efavirenz, tablet (scored) 100 mg and preferably dispersible
  • Etravirine, tablet 25 mg, and preferably dispersible
  • Lamivudine, tablet (scored) 30 mg, and preferably as dispersible
  • Nevirapine, tablet (scored) 20 mg; 100 mg and preferably as dispersible
  • Tenofovir disoproxil fumarate, tablets 150 mg; 200 mg; preferably dispersible
  • Zidovudine, tablet (scored) 60 mg, and preferably as dispersible
  • Abacavir, oral solution, 100 mg/5 ml
  • Tenofovir disoproxil fumarate, oral powder 40 mg/measure

 

The following products were moved to the complementary list of non-priority ARV products

  • Raltegravir, tablet, 400mg
  • Lamivudine/Tenofovir disoproxil fumarate/Efavirenz, tablet, 300mg/300 mg/600 mg

 

The following strengths were added:

  • Lamivudine/Abacavir/Dolutegravir, tablet 60 mg/120 mg/10 mg scored and dispersible